SCHEMBL3801577

SCHEMBL3801577

CCC(=O)C(Cl)C(C)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL509870 0.85 CYP2C9 (0.40)
SCHEMBL15277221 0.79 TSHR (0.42)
SCHEMBL901650 0.78
SCHEMBL28888241 0.76 ALDH1A1 (0.36)
SCHEMBL4115354 0.75 ALDH1A1 (0.46)
SCHEMBL53472 0.75
SCHEMBL13873883 0.74
SCHEMBL2703448 0.73
SCHEMBL1398170 0.72 CA1 (0.38)
SCHEMBL1597955 0.72 SOAT1 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130190366-A1 SUBSTANTIALLY PURE SALTS OF FEBUXOSTAT AND PROCESSES FOR PREPARATION THEREOF CADILA HEALTHCARE LIMITED (IN) 2013-07-25 US disclosed
US-20130190366-A1 SUBSTANTIALLY PURE SALTS OF FEBUXOSTAT AND PROCESSES FOR PREPARATION THEREOF CADILA HEALTHCARE LIMITED (IN) 2013-07-25 US disclosed
US-8389736-B2 Compounds having activity in correcting mutant-CFTR processing and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-03-05 US disclosed
WO-2011101867-A2 SUBSTANTIALLY PURE SALTS OF FEBUXOSTAT AND PROCESSES FOR PREPARATION THEREOF CADILA HEALTHCARE LIMITED (IN) 2011-08-25 WO disclosed
US-20100273839-A1 Compounds Having Activity in Correcting Mutant-CFTR Processing and Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2010-10-28 US disclosed
WO-2009051909-A1 COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT-CFTR CELLULAR PROCESSING AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-04-23 WO disclosed